Psychologists in East Cleveland, OH Accepting Medicare
7 Psychologists found. Showing 1 - 7
 Laniece Matthews Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, East Cleveland, OH 44112 Phone: 216-268-6811 |
Reva R Proctor, DODD CERTIFACTION Psychologist - Mental Retardation & Developmental Disabilities Medicare: Not Enrolled in Medicare Practice Location: 1877 Allandale Ave, East Cleveland, OH 44112 Phone: 216-352-8080 |
Mrs. Karin Merdes Tinnon Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, East Cleveland, OH 44112 Phone: 216-268-6687 Fax: 216-268-6480 |
Marion Gilmore Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, East Cleveland, OH 44112 Phone: 216-268-6650 Fax: 216-268-6496 |
Sylvia Herd Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, Special Education Department, East Cleveland, OH 44112 Phone: 216-268-6349 Fax: 216-268-6676 |
Ms. Susan Pennza Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, East Cleveland, OH 44112 Phone: 216-268-6688 |
Sharrice Taylor Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 1843 Stanwood Rd, East Cleveland, OH 44112 Phone: 216-268-6476 Fax: 216-268-6480 |
News Archive
Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma
Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.
Anticholinergic drugs might increase risk of cognitive impairment, death in older people
A side effect of many commonly used drugs appears to increase the risks of both cognitive impairment and death in older people, according to new research led by the University of East Anglia.
Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.
Protein aggregation is linked to many conformational diseases
Researchers at the Department of Biochemistry and Molecular Biology of Universitat Autònoma de Barcelona (UAB) have revealed the process by which proteins with a tendency to cause conformational diseases such as amyotrophic lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, etc. finally end up causing them.
› Verified 2 days ago
Psychologists
Counselors
Pharmacists
Occupational Therapists
Clinical Social Workers
Dentists